{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:19:20Z","timestamp":1773706760919,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","award":["U01-AI056443"],"award-info":[{"award-number":["U01-AI056443"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.vaccine.2010.11.049","type":"journal-article","created":{"date-parts":[[2010,11,30]],"date-time":"2010-11-30T10:50:46Z","timestamp":1291114246000},"page":"873-877","source":"Crossref","is-referenced-by-count":38,"title":["Highly effective generic adjuvant systems for orphan or poverty-related vaccines"],"prefix":"10.1016","volume":"29","author":[{"given":"Mangala","family":"Rao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina K.","family":"Peachman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary R.","family":"Matyas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sathish B.","family":"Shivachandra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Borschel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venee I.","family":"Morthole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Fernandez-Prada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl R.","family":"Alving","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venigalla B.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2010.11.049_bib0005","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrmicro1681","article-title":"The perfect mix: recent progress in adjuvant research","volume":"5","author":"Guy","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2010.11.049_bib0010","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1586\/14760584.6.5.849","article-title":"New adjuvants: EU regulatory developments","volume":"6","author":"Sesardic","year":"2007","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2010.11.049_bib0015","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1586\/14760584.6.5.723","article-title":"GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives","volume":"6","author":"Gar\u00e7on","year":"2007","journal-title":"Exp Rev Vaccines"},{"key":"10.1016\/j.vaccine.2010.11.049_bib0020","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.it.2008.09.006","article-title":"New horizons in adjuvants for vaccine development","volume":"30","author":"Reed","year":"2009","journal-title":"Trends Immunol"},{"key":"10.1016\/j.vaccine.2010.11.049_bib0025","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1586\/14760584.8.3.293","article-title":"Vaccine adjuvants: scientific challenges and strategic initiatives","volume":"8","author":"Harandi","year":"2009","journal-title":"Exp Rev Vaccines"},{"key":"10.1016\/j.vaccine.2010.11.049_bib0030","unstructured":"FDA. 21 CFR PART 316: Final rule. http:\/\/www.fda.gov\/ForIndustry\/DevelopingProductsforRareDiseasesConditions\/HowtoapplyforOrphanProductDesignation\/ucm124562.htm; 1992."},{"key":"10.1016\/j.vaccine.2010.11.049_bib0035","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1086\/523578","article-title":"Countering anthrax: vaccines and immunoglobulins","volume":"46","author":"Grabenstein","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 4","key":"10.1016\/j.vaccine.2010.11.049_bib0040","doi-asserted-by":"crossref","first-page":"D28","DOI":"10.1016\/j.vaccine.2009.08.102","article-title":"Advances in the development of next-generation anthrax vaccines","volume":"27","author":"Friedlander","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.11.049_bib0045","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.mam.2009.08.006","article-title":"Anthrax vaccination strategies","volume":"30","author":"Cybulski","year":"2009","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.vaccine.2010.11.049_bib0050","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrmicro2129","article-title":"Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule","volume":"7","author":"Sullivan","year":"2009","journal-title":"Nat Rev Microbiol"},{"issue":"Suppl. 3","key":"10.1016\/j.vaccine.2010.11.049_bib0055","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/S0264-410X(02)00174-3","article-title":"Design and selection of vaccine adjuvants: animal models and human trials","volume":"20","author":"Alving","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.11.049_bib0060","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1586\/14760584.2.2.167","article-title":"Survey of human-use adjuvants","volume":"2","author":"Kenney","year":"2003","journal-title":"Exp Rev Vaccines"},{"key":"10.1016\/j.vaccine.2010.11.049_bib0065","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/sj.jim.7000239","article-title":"Production, recovery and immunogenicity of the protective antigen from a recombinant strain of Bacillus anthracis","volume":"28","author":"Ramirez","year":"2002","journal-title":"J Ind Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2010.11.049_bib0070","doi-asserted-by":"crossref","first-page":"94","DOI":"10.2174\/1874226200902010094","article-title":"Ganglioside GM1 binding peptides: a potential adjuvant for transcutaneous immunization","volume":"2","author":"Peachman","year":"2009","journal-title":"Open Immunol J"},{"key":"10.1016\/j.vaccine.2010.11.049_bib0075","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1128\/IAI.74.1.794-797.2006","article-title":"Correlation between lethal toxin-neutralizing antibody titers and protection from intranasal challenge with Bacillus anthracis Ames strain spores in mice after transcutaneous immunization with recombinant anthrax protective antigen","volume":"74","author":"Peachman","year":"2006","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2010.11.049_bib0080","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.virol.2005.10.037","article-title":"In vitro binding of anthrax protective antigen on bacteriophage T4 capsid surface through Hoc\u2013capsid interactions: a strategy for efficient display of large full-length proteins","volume":"345","author":"Shivachandra","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2010.11.049_bib0085","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jmb.2007.05.008","article-title":"Assembly of the small outer capsid protein, Soc, on bacteriophage T4: a novel system for high density display of multiple large anthrax toxins and foreign proteins on phage capsid","volume":"370","author":"Li","year":"2007","journal-title":"J Mol Biol"},{"key":"10.1016\/j.vaccine.2010.11.049_bib0090","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jmb.2009.10.007","article-title":"The structure of the small outer capsid protein, soc: a clamp for stabilizing capsids of T4-like phages","volume":"395","author":"Li","year":"2010","journal-title":"J Mol Biol"},{"key":"10.1016\/j.vaccine.2010.11.049_bib0095","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0076-6879(03)73003-1","article-title":"Oil-in-water liposomal emulsions for vaccine delivery","volume":"373","author":"Matyas","year":"2003","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.vaccine.2010.11.049_bib0100","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1021\/js990011u","article-title":"Oil-in-water liposomal emulsions: characterization and potential use in vaccine delivery","volume":"88","author":"Muderhwa","year":"1999","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2010.11.049_bib0105","doi-asserted-by":"crossref","first-page":"92","DOI":"10.2174\/1875035400902010092","article-title":"Anthrax LFn-PA hybrid antigens: biochemistry, immunogenicity, and protection against lethal ames spore challenge in rabbits","volume":"2","author":"Li","year":"2009","journal-title":"Open Vaccine J"},{"key":"10.1016\/j.vaccine.2010.11.049_bib0110","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.biologicals.2003.09.003","article-title":"Validation of the anthrax lethal toxin neutralization assay","volume":"32","author":"Hering","year":"2004","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2010.11.049_bib0115","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(56)91968-7","article-title":"The use of anthrax antigen to immunize man and monkey","volume":"271","author":"Darlow","year":"1956","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2010.11.049_bib0120","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0264-410X(98)80112-6","article-title":"Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques","volume":"16","author":"Ivins","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.11.049_bib0125","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.vaccine.2009.10.111","article-title":"2010 Comparative performance of a licensed anthrax vaccine versus electroporation based delivery of a PA encoding DNA vaccine in rhesus macaques","volume":"28","author":"Livingston","year":"2010","journal-title":"Vaccine"},{"issue":"Suppl. 3","key":"10.1016\/j.vaccine.2010.11.049_bib0130","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S0264-410X(02)00166-4","article-title":"Aluminum salts in vaccines\u2014US perspective","volume":"20","author":"Baylor","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.11.049_bib0135","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1128\/IAI.60.6.2438-2444.1992","article-title":"Adjuvant effects of liposomes containing lipid A: enhancement of liposomal antigen presentation and recruitment of macrophages","volume":"60","author":"Verma","year":"1992","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2010.11.049_bib0140","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.0818-9641.2004.01283.x","article-title":"Immunostimulatory CpG motifs induce CTL responses to HIV type I oligomeric gp140 envelope protein","volume":"82","author":"Rao","year":"2004","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.vaccine.2010.11.049_bib0145","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/scientificamerican1009-72","article-title":"Boosting vaccine power","volume":"301","author":"Gar\u00e7on","year":"2009","journal-title":"Sci Am"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1001683X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1001683X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,14]],"date-time":"2020-06-14T05:45:05Z","timestamp":1592113505000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1001683X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0264410X1001683X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2010.11.049","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}